Plain-English translation of NCT06469281 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called 27T51, which is a type of immune cell therapy designed to recognize and attack ovarian cancer cells. Researchers are studying whether this treatment works better when given alone or combined with other cancer drugs. The goal is to find a safe and effective option for people whose cancer has returned or stopped responding to standard treatments.
Ovarian cancer that comes back after treatment or doesn't respond to standard therapies is very difficult to treat, and patients need new options. This medication represents a different approach — using the body's own immune cells to fight the cancer — and this trial will test whether it can help where other treatments have failed.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo a procedure to collect immune cells from your blood (called leukapheresis), which are then modified in the laboratory and given back to you as an infusion. Depending on which group you're assigned to, you may receive the medication alone or combined with other cancer drugs. You will have regular visits to the clinic for blood work, scans, and check-ups to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States